Due to ADAR involvement in protein diversity and gene expression regulation, when ADAR editing or ADAR expression is dysregulated, this can lead to cancer promotion or the downregulation of tumor suppressor pathways, making ADAR1 and ADAR2 appealing drug targets for oncology. This evidence concerns the gene ADAR and neoplasm.